Tenofovir disoproxil fumarate as pre-exposure prophylaxis for HIV prevention in women with osteoporosis: a case report and review of the literature

被引：0
|
作者：
Patel, Rupa R. [1 ]
Presti, Rachel [1 ]
Harrison, Laura C. [1 ]
Powderly, William G. [1 ]
Chan, Philip A. [2 ]
机构：
[1] Washington Univ, Div Infect Dis, St Louis, MO 63130 USA
[2] Brown Univ, Div Infect Dis, Providence, RI 02912 USA
来源：
ANTIVIRAL THERAPY | 2018年 / 23卷 / 04期
基金：
美国国家卫生研究院;
关键词：
BONE-MINERAL DENSITY; DOUBLE-BLIND; EMTRICITABINE; INFECTION; FRACTURES;
D O I：
10.3851/IMP3208
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Pre-exposure prophylaxis (PrEP), using tenofovir disoproxil fumarate (TDF), can effectively prevent HIV acquisition. However, TDF can cause changes in bone mineral density (BMD). There is little information on the use of PrEP among patients with bone disease. We present a case report of a female with pre-existing osteoporosis who was prescribed PrEP. Over the course of 9 months of consistent PrEP use, verified by dried blood spot testing, we report a lack of BMD changes on serial dual-emission X-ray absorptiometry scans in this patient. This case can inform PrEP care for patients with pre-existing bone disease.
引用
收藏
页码：379 / 382
页数：4
相关论文
共 50 条
  • [1] Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention
    Mugwanya, Kenneth K.
    Baeten, Jared M.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2016, 15 (02) : 265 - 273
  • [2] Safety review of tenofovir disoproxil fumarate/emtricitabine pre-exposure prophylaxis for pregnant women at risk of HIV infection
    Stalter, Randy M.
    Pintye, Jillian
    Mugwanya, Kenneth K.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2021, 20 (11) : 1367 - 1374
  • [3] HIV prevention: response to pre-exposure prophylaxis failure with tenofovir disoproxil
    Fox, Julie
    Collins, Simon
    [J]. AIDS, 2017, 31 (09) : 1343 - 1343
  • [4] Emtricitabine/Tenofovir Disoproxil Fumarate: A Review of its Use in HIV-1 Pre-Exposure Prophylaxis
    Greg L. Plosker
    [J]. Drugs, 2013, 73 : 279 - 291
  • [5] Emtricitabine/Tenofovir Disoproxil Fumarate: A Review of its Use in HIV-1 Pre-Exposure Prophylaxis
    Plosker, Greg L.
    [J]. DRUGS, 2013, 73 (03) : 279 - 291
  • [6] Acceptability of a Tenofovir Disoproxil Fumarate Intravaginal Ring for HIV Pre-Exposure Prophylaxis Among Sexually Active Women
    Dobkin, April
    McWalters, Jessica
    Barnett, Rebecca
    Ray, Laurie L.
    Espinoza, Lilia
    McGinn, Aileen P.
    Atrio, Jessica M.
    Keller, Marla J.
    [J]. SEXUALLY TRANSMITTED DISEASES, 2020, 47 (12) : 819 - 824
  • [7] Design and evaluation of mucoadhesive vaginal tablets of tenofovir disoproxil fumarate for pre-exposure prophylaxis of HIV
    Khan, Arshad Bashir
    Thakur, Ram Sharnagat
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2018, 44 (03) : 472 - 483
  • [8] Pre-exposure prophylaxis failure with tenofovir disoproxil
    Streeck, Hendrik
    Verheyen, Jens
    Storim, Julian
    Dittmer, Ulf
    Jochum, Christoph
    Timm, Jrg
    Esser, Stefan
    [J]. AIDS, 2017, 31 (01) : 176 - 177
  • [9] Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women
    Mugwanya, Kenneth K.
    John-Stewart, Grace
    Baeten, Jared
    [J]. EXPERT OPINION ON DRUG SAFETY, 2017, 16 (07) : 867 - 871
  • [10] Model-informed intermittent tenofovir disoproxil fumarate and emtricitabine dosing for HIV pre-exposure prophylaxis in subjects with renal impairment: a case report
    Zino, Leena
    Jacobs, Tom G.
    Nieuwenstein, Thomas
    Grintjes, Karin
    Colbers, Angela
    Burger, David M.
    [J]. AIDS, 2023, 37 (02) : 363 - 365
12345